2-[1-(3-chloro-5-methoxy-7-methyl-1H-indol-4-yl)-1-hydroxyethyl]-1,3-dihydroisoindole-5-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[1-(3-chloro-5-methoxy-7-methyl-1H-indol-4-yl)-1-hydroxyethyl]-1,3-dihydroisoindole-5-carbonitrile
• 化学式: C₂₁H₂₀ClN₃O₂
• 分子量: 381.9
• InChiKey: JDAHEUZQIVGQRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  72.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• SYNTHESIS OF AVRAINVILLAMIDE, STREPHACIDIN B, AND ANALOGUES THEREOF
  申请人：Myers Andrew G.

  公开号：US20090143581A1

  公开（公告）日：2009-06-04

  The syntheses of the natural products, avrainvillamide and stephacidin B, are provided. The α,β-unsaturated nitrone functionality of avrainvillamide and its 3-alkylidene-3H-indole 1-oxide core is shown to covalently and reversibly bond to heteroatom-based nucleophiles. This capability may allow these molecules to bind active site nucleophiles and may provide the basis for designing potent and selective enzyme inhibitors. Both avrainvillamide and its dimer stephacidin B have been reported to exhibit antiproliferative activity, and avrainvillamide has been reported to exhibit antimicrobial activity against multi-drug resistant bacteria. Avrainvillamide has been found to target cytoskeleton-linking membrane protein (CLIMP-63) thereby preventing cells from undergoing mitosis. The invention provides syntheses of these natural products as well as analogs of these natural products and their functional cores. The compounds of the invention may be used in the treatment of diseases such as cancer, autoimmune diseases, and bacterial infection.

  本文提供了天然产物avrinvillamide和stephacidin B的合成方法。avrinvillamide的α，β-不饱和亚硝基功能和其3-烷基亚甲基-3H-吲哚1-氧化物核心被证明可以共价可逆地结合到基于杂原子的亲核试剂上。这种能力可能使这些分子能够结合到活性位点的亲核试剂，并为设计有效和选择性的酶抑制剂提供基础。avrinvillamide和其二聚体stephacidin B均已报道具有抗增殖活性，avrinvillamide也已报道具有对多药耐药细菌的抗菌活性。发现avrinvillamide的靶点是细胞骨架连接膜蛋白(CLIMP-63)，从而防止细胞进行有丝分裂。本发明提供了这些天然产物以及它们的类似物和功能核心的合成方法。本发明的化合物可以用于治疗癌症、自身免疫性疾病和细菌感染等疾病。
• COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
  申请人：Novartis AG

  公开号：EP2855456A1

  公开（公告）日：2015-04-08
• [EN] COMPLEMENT PATHWAY MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES VOIES DU COMPLÉMENT ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2013164802A1

  公开（公告）日：2013-11-07

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.